The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Functional improvement of dystrophic muscle by myostatin blockade
Abstract
Mice and cattle with mutations in the myostatin (GDF8) gene show a marked increase in body weight and muscle mass, indicating that this new member of the TGF-beta superfamily is a negative regulator of skeletal muscle growth. Inhibition of the myostatin gene product is predicted to increase muscle mass and improve the disease phenotype in a variety of primary and secondary myopathies. We tested the ability of inhibition of myostatin in vivo to ameliorate the dystrophic phenotype in the mdx mouse model of Duchenne muscular dystrophy (DMD). Blockade of endogenous myostatin by using intraperitoneal injections of blocking antibodies for three months resulted in an increase in body weight, muscle mass, muscle size and absolute muscle strength in mdx mouse muscle along with a significant decrease in muscle degeneration and concentrations of serum creatine kinase. The functional improvement of dystrophic muscle by myostatin blockade provides a novel, pharmacological strategy for treatment of diseases associated with muscle wasting such as DMD, and circumvents the major problems associated with conventional gene therapy in these disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The interest in myostatin was generated by recent studies where antibodies for myostatin were created and administered to adult rodents, which resulted in an increase in body mass, muscle mass, muscle size, and strength [11,12].”
From Effects of methoxyisoflavone, ecdysterone, and sulfo-polysaccharide supplementation on training adaptations in resistance-trained males (2006) · cites this paper as [12]
Citations
Cites
Textbook of Medical Physiology
(1966) · Annals of Internal Medicine · doi:10.7326/0003-4819-64-6-1363_2 · Cited by 9,749
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
TEXTBOOK OF MEDICAL PHYSIOLOGY
GUYTON, A. C. (1967) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196701000-00031 · Cited by 2,837
Dystrophin expression in the mdx mouse restored by stem cell transplantation
Gussoni, E., Soneoka, Y., Strickland, C. D., Buzney, E. A., Khan, M. K., Flint, A. F., Kunkel, L. M., & Mulligan, R. C. (1999) · Nature · doi:10.1038/43919 · Cited by 1,802 · cited 1×
“In comparison with conventional transgenic, cell and gene therapy approache”
BackgroundX chromosome-linked muscular dystrophy (mdx) in the mouse
Bulfield, G., Siller, W. G., Wight, P. A., & Moore, K. J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.4.1189 · Cited by 1,765
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616 · cited 1×
“Alterations in Smad 2 and 3 phosphorylation would be predicted to regulate the formation of Smad complexes, their nuclear translocation and transcriptional regulation of genes associated with commitment of muscle progenitor”
BackgroundA deletion in the bovine myostatin gene causes the double–muscled phenotype in cattle
Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-71 · Cited by 1,556
Dystrophin protects the sarcolemma from stresses developed during muscle contraction
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., & Sweeney, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3710 · Cited by 1,526 · cited 1×
“The regimen did not completely reverse dystrophic changes; physiological parameters evaluated by ex vivo tests, such as susceptibility to damage by lengthening contraction”
BackgroundAhima, R. S., & Flier, J. S. (2000) · Annual Review of Physiology · doi:10.1146/annurev.physiol.62.1.413 · Cited by 1,428
Self-citation
Research works printed but not linked: 2
- Jalenak, M. et al. Transcriptional changes arising from in vivo inhibition of myostatin. J. Neurol. Sci. 199 (suppl)., S83 (2002)
- Engel, A. G. & Franzini-Armstrong, C. Myology (McGraw-Hill, New York, 1994)
Cited by
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways
Fearon, K. C. H., Glass, D. J., & Guttridge, D. C. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.06.011 · Cited by 1,205
“, 2002), and conversely, inhibition by various genetic means promotes a doubling in muscle mass and myofiber size (Bogdanovich et al., 2002; Whittemore et al., 2003; Lee et al., 2005; Welle et al., 2007).”
BackgroundMuscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
The Molecular Basis of Skeletal Muscle Atrophy
Jackman, R. W., & Kandarian, S. C. (2004) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00579.2003 · Cited by 1,008
“It appears that mdx mice injected with myostatin antibodies for 3 mo showed an increase in muscle mass (11).”
BackgroundREGULATION OF MUSCLE MASS BY MYOSTATIN
Lee, S.-J. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.012103.135836 · Cited by 819
Exercise is the real polypill.
Fiuza-Luces, C., Garatachea, N., Berger, N. A., & Lucia, A. (2013) · Physiology · doi:10.1152/physiol.00019.2013 · Cited by 791
“Although myostatin increases might contribute to insulin resistance (184, 360), obesity (185), muscle wasting (63, 70, 97, 154), or agingsarcopenia (523), its loss/inhibition decreases adiposity (164, 303, 521, 530), induces browning of the white adipose tissue [through AMPK-peroxisome proliferator-activated receptor-…”
BackgroundMyostatin negatively regulates satellite cell activation and self-renewal
McCroskery, S., Thomas, M., Maxwell, L., Sharma, M., & Kambadur, R. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200207056 · Cited by 784
“Also, the injection of a specific antibody to Myostatin into the mdx mice alleviated the severity of the phenotype; in fact, the mice gained muscle mass and increased the production of the muscle protein creatine kinase, indicating improvement of muscle strength (Bogdanovich et al., 2002).”
BackgroundCohn, R. D., van Erp, C., Habashi, J. P., Soleimani, A. A., Klein, E. C., Lisi, M. T., Gamradt, M., ap Rhys, C. M., Holm, T. M., Loeys, B. L., et al. (2007) · Nature Medicine · doi:10.1038/nm1536 · Cited by 669
“Myostatin antagonism has been shown to ameliorate the muscle phenotype in dystrophin-deficient mdx mic”
BackgroundRole of transforming growth factor-β superfamily signaling pathways in human disease
Gordon, K. J., & Blobe, G. C. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.01.006 · Cited by 641
Sampaolesi, M., Torrente, Y., Innocenzi, A., Tonlorenzi, R., D'Antona, G., Pellegrino, M. A., Barresi, R., Bresolin, N., De Angelis, M. G. C., Campbell, K. P., et al. (2003) · Science · doi:10.1126/science.1082254 · Cited by 641
Rebbapragada, A., Benchabane, H., Wrana, J. L., Celeste, A. J., & Attisano, L. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.20.7230-7242.2003 · Cited by 565
“Myostatin-null mice display widespread increases in muscle mass (36) and decreased body fat accumulation (28, 38), and inhibition of myostatin with blocking antibodies increases muscle mass (8).”
BackgroundInhibition of myostatin in adult mice increases skeletal muscle mass and strength
Whittemore, L.-A., Song, K., Li, X., Aghajanian, J., Davies, M., Girgenrath, S., Hill, J. J., Jalenak, M., Kelley, P., Knight, A., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02953-4 · Cited by 503
“Others have used the same antibody and made similar observations in developing mice with muscular dystrophy [35].”
Self-citationRegulation of muscle growth by multiple ligands signaling through activin type II receptors
Lee, S.-J., Reed, L. A., Davies, M. V., Girgenrath, S., Goad, M. E. P., Tomkinson, K. N., Wright, J. F., Barker, C., Ehrmantraut, G., Holmstrom, J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505996102 · Cited by 501
McFarlane, C., Plummer, E., Thomas, M., Hennebry, A., Ashby, M., Ling, N., Smith, H., Sharma, M., & Kambadur, R. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20757 · Cited by 480
“Functional Myostatin blockade in mdx mice, a model of Duchenne Muscular Dystrophy, results in an increase in muscle mass and more importantly, muscle force production (Bogdanovich et al., 2002).”
BackgroundA phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy
Wagner, K. R., Fleckenstein, J. L., Amato, A. A., Barohn, R. J., Bushby, K., Escolar, D. M., Flanigan, K. M., Pestronk, A., Tawil, R., Wolfe, G. I., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21338 · Cited by 481
“Furthermore, postnatal inhibition of myostatin with a neutralizing monoclonal antibody to myostatin also ameliorated disease features in the mdx mouse.(15) Given these preclinical results, myostatin has been considered a therapeutic target for the treatment of muscular dystrophy.”
BackgroundLi, Y., Foster, W., Deasy, B. M., Chan, Y., Prisk, V., Tang, Y., Cummins, J., & Huard, J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63188-4 · Cited by 451
Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases
Wolfman, N. M., McPherron, A. C., Pappano, W. N., Davies, M. V., Song, K., Tomkinson, K. N., Wright, J. F., Zhao, L., Sebald, S. M., Greenspan, D. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2534946100 · Cited by 454
Molecular mechanisms modulating muscle mass
Glass, D. J. (2003) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(03)00138-2 · Cited by 440
Lack of myostatin results in excessive muscle growth but impaired force generation
Amthor, H., Macharia, R., Navarrete, R., Schuelke, M., Brown, S. C., Otto, A., Voit, T., Muntoni, F., Vrbóva, G., Partridge, T., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604893104 · Cited by 425
Guo, T., Jou, W., Chanturiya, T., Portas, J., Gavrilova, O., & McPherron, A. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004937 · Cited by 402
“mass in both healthy adult mice and in mouse models of muscular dystrophy [4,5,6,7,8,9,10,11].”
Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis
Amthor, H., Nicholas, G., McKinnell, I., Kemp, C. F., Sharma, M., Kambadur, R., & Patel, K. (2004) · Developmental Biology · doi:10.1016/j.ydbio.2004.01.046 · Cited by 401
Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial
Becker, C., Lord, S. R., Studenski, S. A., Warden, S. J., Fielding, R. A., Recknor, C. P., Hochberg, M. C., Ferrari, S. L., Blain, H., Binder, E. F., et al. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00298-3 · Cited by 381
Excess TGF-β mediates muscle weakness associated with bone metastases in mice
Waning, D. L., Mohammad, K. S., Reiken, S., Xie, W., Andersson, D. C., John, S., Chiechi, A., Wright, L. E., Umanskaya, A., Niewolna, M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3961 · Cited by 378
Nowak, K. J., & Davies, K. E. (2004) · EMBO reports · doi:10.1038/sj.embor.7400221 · Cited by 357
“The use of antibodies to specifically block the action of either myostatin (a member of the transforming growth factor-β (TGF-β) superfamily; Bogdanovich et al, 2002), or tumour necrosis factor-α (TNF-α; Grounds & Torrisi, 2004), has led to the functional improvement of dystrophic muscle in the…”
BackgroundGrounds, M. D., Radley, H. G., Lynch, G. S., Nagaraju, K., & De Luca, A. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.03.008 · Cited by 344
“The Rotarod measures overall motor coordination; this is a motorised rotating treadmill which requires mice to maintain their grip and balance on a rotating drum, or simply lose their balance and fall off (Bogdanovich et al., 2002; Ozawa et al., 2006; Payne et al., 2006).”
Minetti, G. C., Colussi, C., Adami, R., Serra, C., Mozzetta, C., Parente, V, Fortuni, S., Straino, S., Sampaolesi, M., Di Padova, M., et al. (2006) · Nature Medicine · doi:10.1038/nm1479 · Cited by 339
Cancer cachexia: molecular mechanisms and treatment strategies
Setiawan, T., Sari, I. N., Wijaya, Y. T., Julianto, N. M., Muhammad, J. A., Lee, H., Chae, J. H., & Kwon, H. Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01454-0 · Cited by 315
Zhang, L., Rajan, V., Lin, E., Hu, Z., Han, H. Q., Zhou, X., Song, Y., Min, H., Wang, X., Du, J., et al. (2011) · The FASEB Journal · doi:10.1096/fj.10-176917 · Cited by 316
“Because muscle growth in genetic models of muscle dystrophy increases when myostatin is inhibited (18), we tested whether injections of the anti-myostatin peptibody would block muscle atrophy induced by a complex metabolic disorder such as CKD.”
BackgroundQuadrupling Muscle Mass in Mice by Targeting TGF-ß Signaling Pathways
Lee, S.-J. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000789 · Cited by 316
RNAi-based drug design: considerations and future directions
Tang, Q., & Khvorova, A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00912-9 · Cited by 282
“Therapeutic modulation of myostatin may be beneficial for treating muscular dystrophies 178–180 .”
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential
Han, H. Q., Zhou, X., Mitch, W. E., & Goldberg, A. L. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.019 · Cited by 314
Advances in signaling in vertebrate regeneration as a prelude to regenerative medicine
Stoick-Cooper, C. L., Moon, R. T., & Weidinger, G. (2007) · Genes & Development · doi:10.1101/gad.1540507 · Cited by 308
“Furthermore, administration of Myostatinneutralizing antibodies increases muscle mass and muscle strength in Mdx mice, which serve as a model for Duchenne muscular dystrophy (Bogdanovich et al. 2002).”
BackgroundThe Pathogenesis and Therapy of Muscular Dystrophies
Guiraud, S., Aartsma-Rus, A., Vieira, N. M., Davies, K. E., van Ommen, G.-J. B., & Kunkel, L. M. (2015) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090314-025003 · Cited by 302
“Myostatin blockade by any of several agents—such as myostatin antibodies (28), myostatin propeptides (18, 214), the active form of mutated myostatin (206), small leucine-rich proteoglycans such as decorin (94), or activin receptor IIB (139)—ameliorates the pathology in the mdx mouse.”
BackgroundMUSCLE DAMAGE IN MDX (DYSTROPHIC) MICE: ROLE OF CALCIUM AND REACTIVE OXYGEN SPECIES
Whitehead, N. P., Yeung, E. W., & Allen, D. G. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04394.x · Cited by 293
Myostatin Gene Deletion Prevents Glucocorticoid-Induced Muscle Atrophy
Gilson, H., Schakman, O., Combaret, L., Lause, P., Grobet, L., Attaix, D., Ketelslegers, J. M., & Thissen, J. P. (2007) · Endocrinology · doi:10.1210/en.2006-0539 · Cited by 278
“Nevertheless, blockage of endogenous myostatin either by injections of blocking antibodies or postnatal gene excision resulted in an increase in muscle mass and strength in normal (40, 41) and mdx dystrophic mice.”
Colussi, C., Mozzetta, C., Gurtner, A., Illi, B., Rosati, J., Straino, S., Ragone, G., Pescatori, M., Zaccagnini, G., Antonini, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805514105 · Cited by 275
Excitation‐transcription coupling in skeletal muscle: the molecular pathways of exercise
Gundersen, K. (2011) · Biological Reviews · doi:10.1111/j.1469-185x.2010.00161.x · Cited by 251
“In adult animals inhibition of myostatin with antibodies leads to hypertrophy without an increase in the number of fibres (Bogdanovich et al., 2002); conversely, overexpression of myostatin in muscle fibres after electroporation leads to muscle atrophy without loss of muscle fibres (Durieux et al.”
BackgroundHaidet, A. M., Rizo, L., Handy, C., Umapathi, P., Eagle, A., Shilling, C., Boue, D., Martin, P. T., Sahenk, Z., Mendell, J. R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709144105 · Cited by 267
“Delivery of neutralizing antibodies against myostatin has shown promise in dystrophic mdx mice (10), yet there have been varying reports on the efficacy to enhance muscles when delivered in aged animals (11).”
BackgroundRegulation of Muscle Mass by Follistatin and Activins
Lee, S.-J., Lee, Y.-S., Zimmers, T. A., Soleimani, A., Matzuk, M. M., Tsuchida, K., Cohn, R. D., & Barton, E. R. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0127 · Cited by 273
Self-citationMyostatin Directly Regulates Skeletal Muscle Fibrosis
Li, Z. B., Kollias, H. D., & Wagner, K. R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802585200 · Cited by 262
A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy
Mendell, J. R., Sahenk, Z., Malik, V., Gomez, A. M., Flanigan, K. M., Lowes, L. P., Alfano, L. N., Berry, K., Meadows, E., Lewis, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.200 · Cited by 246
Gilson, H., Schakman, O., Kalista, S., Lause, P., Tsuchida, K., & Thissen, J.-P. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00193.2009 · Cited by 248
“Duchenne muscular dystrophy (DMD) (4, 45).”
Iezzi, S., Di Padova, M., Serra, C., Caretti, G., Simone, C., Maklan, E., Minetti, G., Zhao, P., Hoffman, E. P., Puri, P. L., et al. (2004) · Developmental Cell · doi:10.1016/s1534-5807(04)00107-8 · Cited by 239
Role of TGF-β signaling in inherited and acquired myopathies
Burks, T. N., & Cohn, R. D. (2011) · Skeletal Muscle · doi:10.1186/2044-5040-1-19 · Cited by 233
“Inhibiting MSTN in various myopathic conditions has yielded mixed results, depending on the disease model and mechanism of inhibition [43,44,48,50,78-100] (Table 2).”
BackgroundMyostatin propeptide‐mediated amelioration of dystrophic pathophysiology
Bogdanovich, S., Perkins, K. J., Krag, T. O. B., Whittemore, L.-A., & Khurana, T. S. (2005) · The FASEB Journal · doi:10.1096/fj.04-2796com · Cited by 242
“The disease is caused by mutations in the DMD gene resulting in quantitative and/or qualitative disturbances in expression of the gene product, dystrophin (1, 2).”
InfluentialSelf-citationClinical, Agricultural, and Evolutionary Biology of Myostatin: A Comparative Review
Rodgers, B. D., & Garikipati, D. K. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0003 · Cited by 237
Campbell, C., McMillan, H. J., Mah, J. K., Tarnopolsky, M., Selby, K., McClure, T., Wilson, D. M., Sherman, M. L., Escolar, D., & Attie, K. M. (2017) · Muscle & Nerve · doi:10.1002/mus.25268 · Cited by 240
Anti‐TNFα (Remicade®) therapy protects dystrophic skeletal muscle from necrosis
Grounds, M. D., & Torrisi, J. (2004) · The FASEB Journal · doi:10.1096/fj.03-1024com · Cited by 235
Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure
Heineke, J., Auger-Messier, M., Xu, J., Sargent, M., York, A., Welle, S., & Molkentin, J. D. (2010) · Circulation · doi:10.1161/circulationaha.109.882068 · Cited by 238
Girgenrath, S., Song, K., & Whittemore, L.-A. (2005) · Muscle & Nerve · doi:10.1002/mus.20175 · Cited by 228
Self-citationPharmacological strategies for muscular dystrophy
Khurana, T. S., & Davies, K. E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1085 · Cited by 225
Self-citationThe bone morphogenetic protein axis is a positive regulator of skeletal muscle mass
Winbanks, C. E., Chen, J. L., Qian, H., Liu, Y., Bernardo, B. C., Beyer, C., Watt, K. I., Thomson, R. E., Connor, T., Turner, B. J., et al. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211134 · Cited by 225
Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null mice
McCroskery, S., Thomas, M., Platt, L., Hennebry, A., Nishimura, T., McLeay, L., Sharma, M., & Kambadur, R. (2005) · Journal of Cell Science · doi:10.1242/jcs.02482 · Cited by 214
“From the pharmacological point of view, antagonizing Mstn should be a viable drug option for muscle growth in muscular dystrophy (Bogdanovich et al., 2002), sarcopenia and cachexia (Zimmers et al., 2002).”
BackgroundDominique, J.-E., & Gérard, C. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.04.012 · Cited by 207
Muscle hypertrophy driven by myostatin blockade does not require stem/precursor-cell activity
Amthor, H., Otto, A., Vulin, A., Rochat, A., Dumonceaux, J., Garcia, L., Mouisel, E., Hourdé, C., Macharia, R., Friedrichs, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811129106 · Cited by 198
“As a further indicator of regenerative activity, we analyzed the frequency of dystrophin-positive ‘‘revertant’’ fibers found sporadically in both mdx and DMD muscles (Fig.”
BackgroundMethodInfluentialActivin signaling as an emerging target for therapeutic interventions
Tsuchida, K., Nakatani, M., Hitachi, K., Uezumi, A., Sunada, Y., Ageta, H., & Inokuchi, K. (2009) · Cell Communication and Signaling · doi:10.1186/1478-811x-7-15 · Cited by 195
“Monoclonal antibody-mediated myostatin blockade results in an increase of muscle mass and absolute muscle strength in mdx mice, an animal model of Duchenne-type muscular dystrophy [60].”
Current Status of Pharmaceutical and Genetic Therapeutic Approaches to Treat DMD
Pichavant, C., Aartsma-Rus, A., Clemens, P. R., Davies, K. E., Dickson, G., Takeda, S., Wilton, S. D., Wolff, J. A., Wooddell, C. I., Xiao, X., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.59 · Cited by 193
Impaired membrane resealing and autoimmune myositis in synaptotagmin VII–deficient mice
Chakrabarti, S., Kobayashi, K. S., Flavell, R. A., Marks, C. B., Miyake, K., Liston, D. R., Fowler, K. T., Gorelick, F. S., & Andrews, N. W. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200305131 · Cited by 205
“Quantitative, kinetic determination of creatine kinase in serum of control and Syt VII / mice was performed as described previously (Bogdanovich et al., 2002).”
BackgroundMethodTendons of myostatin-deficient mice are small, brittle, and hypocellular
Mendias, C. L., Bakhurin, K. I., & Faulkner, J. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707069105 · Cited by 192
Qian, L., Tang, M., Yang, J., Wang, Q., Cai, C., Jiang, S., Li, H., Jiang, K., Gao, P., Ma, D., et al. (2015) · Scientific Reports · doi:10.1038/srep14435 · Cited by 189
Johns, N., Stephens, N. A., & Fearon, K. C. H. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.032 · Cited by 183
Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease
Rodino‐Klapac, L. R., Haidet, A. M., Kota, J., Handy, C., Kaspar, B. K., & Mendell, J. R. (2009) · Muscle & Nerve · doi:10.1002/mus.21244 · Cited by 194
Drug screening in a zebrafish model of Duchenne muscular dystrophy
Kawahara, G., Karpf, J. A., Myers, J. A., Alexander, M. S., Guyon, J. R., & Kunkel, L. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102116108 · Cited by 191
“Other treatments currently being tested or considered for treating muscular dystrophy include the small molecule PTC124, which promotes read-through of nonsense mutations (3), encouraging muscle development by myostatin down-regulation (4, 5), and the use of oligonucleotides to promote exon skipping to restore dystrop…”
BackgroundBone and skeletal muscle: neighbors with close ties
DiGirolamo, D. J., Kiel, D. P., & Esser, K. A. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1969 · Cited by 193
Muscle regeneration in the prolonged absence of myostatin
Wagner, K. R., Liu, X., Chang, X., & Allen, R. E. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408729102 · Cited by 187
Nakatani, M., Takehara, Y., Sugino, H., Matsumoto, M., Hashimoto, O., Hasegawa, Y., Murakami, T., Uezumi, A., Takeda, S., Noji, S., et al. (2008) · The FASEB Journal · doi:10.1096/fj.07-8673com · Cited by 187
Mammalian animal models for Duchenne muscular dystrophy
Willmann, R., Possekel, S., Dubach-Powell, J., Meier, T., & Ruegg, M. A. (2009) · Neuromuscular Disorders · doi:10.1016/j.nmd.2008.11.015 · Cited by 181
“07 at 8w [70]r Twitch force (mN) Edl, 16w: 130 [72] Edl, 8w: 12 [20] Sol, 8w: 12 [20] Stm, 8w: 50 [46] Normalized twitch force (mN/mm(2) CSA) Edl, 10w: 50 [19] Sol, 10w: 40 [19] Dia, 10w: 20 [19] Dia, 7w: 5.”
Modulating skeletal muscle mass by postnatal, muscle‐specific inactivation of the myostatin gene
Grobet, L., Pirottin, D., Farnir, F., Poncelet, D., Royo, L. J., Brouwers, B., Christians, E., Desmecht, D., Coignoul, F., Kahn, R., et al. (2003) · genesis · doi:10.1002/gene.10188 · Cited by 180
“…indicating that 1) postnatal systemic administration of myostatin causes cachexia in the mouse (Zimmers et al., 2002); and 2) antibody-mediated blockade of endogenous myostatin results in an increase in muscle mass and reduction of muscle degeneration in mdx mice (Bogdanovitch et al., 2002).”
BackgroundProdomains of Transforming Growth Factor β (TGFβ) Superfamily Members Specify Different Functions
Sengle, G., Ono, R. N., Sasaki, T., & Sakai, L. Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.188615 · Cited by 182
The central role of myostatin in skeletal muscle and whole body homeostasis
Elliott, B., Renshaw, D., Getting, S., & Mackenzie, R. (2012) · Acta Physiologica · doi:10.1111/j.1748-1716.2012.02423.x · Cited by 183
“Indeed, to the best of the authors’ knowledge, excluding the results of Bogdanovich et al. (2002) for the above-mentioned reasons, no reports of muscle pathology have been seen with in vivo myostatin inhibitory studies.”
InfluentialMuscle myostatin signalling is enhanced in experimental cancer cachexia
Costelli, P., Muscaritoli, M., Bonetto, A., Penna, F., Reffo, P., Bossola, M., Bonelli, G., Doglietto, G. B., Baccino, F. M., & Fanelli, F. R. (2008) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2008.01970.x · Cited by 181
Activin A more prominently regulates muscle mass in primates than does GDF8
Latres, E., Mastaitis, J., Fury, W., Miloscio, L., Trejos, J., Pangilinan, J., Okamoto, H., Cavino, K., Na, E., Papatheodorou, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms15153 · Cited by 185
LeBrasseur, N. K., Schelhorn, T. M., Bernardo, B. L., Cosgrove, P. G., Loria, P. M., & Brown, T. A. (2009) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glp068 · Cited by 180
Limb-Girdle Muscular Dystrophy in the United States
Moore, S. A., Shilling, C. J., Westra, S., Wall, C., Wicklund, M. P., Stolle, C., Brown, C. A., Michele, D. E., Piccolo, F., Winder, T. L., et al. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000235854.77716.6c · Cited by 181
“These therapies include gene transfer (64Y66), exon skipping (67), stop codon suppression (68), and myostatin inhibition (69).”
BackgroundWozniak, A. C., Kong, J., Bock, E., Pilipowicz, O., & Anderson, J. E. (2005) · Muscle & Nerve · doi:10.1002/mus.20263 · Cited by 176
A single ascending‐dose study of muscle regulator ace‐031 in healthy volunteers
Attie, K. M., Borgstein, N. G., Yang, Y., Condon, C. H., Wilson, D. M., Pearsall, A. E., Kumar, R., Willins, D. A., Seehra, J. S., & Sherman, M. L. (2013) · Muscle & Nerve · doi:10.1002/mus.23539 · Cited by 176
TGFβ and BMP signaling in skeletal muscle: potential significance for muscle-related disease
Sartori, R., Gregorevic, P., & Sandri, M. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.06.002 · Cited by 177
Skeletal muscle atrophy: Potential therapeutic agents and their mechanisms of action
Dutt, V., Gupta, S., Dabur, R., Injeti, E., & Mittal, A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.05.010 · Cited by 174
New therapies for Duchenne muscular dystrophy: challenges, prospects and clinical trials
Cossu, G., & Sampaolesi, M. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.10.003 · Cited by 173
“Theuseof antibodies specifically to block the action of myostatin [ 58 ] has led to functional improvement of dystrophic muscle in mice.”
BackgroundStrength at the extracellular matrix–muscle interface
Grounds, M. D., Sorokin, L., & White, J. (2005) · Scandinavian Journal of Medicine & Science in Sports · doi:10.1111/j.1600-0838.2005.00467.x · Cited by 167
“…reduced dystropathology in mdx mice is seen when the growth factor myostatin is absent (Wagner et al., 2002) or blocked by specific antibodies (Bogdanovich et al., 2002), and by overexpression of membraneassociated proteins such as utrophin (Khurana & Davies, 2003), integrin a7 (Burkin et…”
BackgroundFollistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates
Kota, J., Handy, C. R., Haidet, A. M., Montgomery, C. L., Eagle, A., Rodino-Klapac, L. R., Tucker, D., Shilling, C. J., Therlfall, W. R., Walker, C. M., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000112 · Cited by 166
“Indeed, injection of a neutralizing monoclonal antibody to myostatin led to increased skeletal muscle mass in mice without undue side effects (22).”
BackgroundMiller, T. M., Kim, S. H., Yamanaka, K., Hester, M., Umapathi, P., Arnson, H., Rizo, L., Mendell, J. R., Gage, F. H., Cleveland, D. W., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609411103 · Cited by 160
Kwak, J. Y., & Kwon, K.-S. (2019) · Annals of Geriatric Medicine and Research · doi:10.4235/agmr.19.0028 · Cited by 171
Myostatin promotes the terminal differentiation of embryonic muscle progenitors
Manceau, M., Gros, J., Savage, K., Thomé, V., McPherron, A. C., Paterson, B., & Marcelle, C. (2008) · Genes & Development · doi:10.1101/gad.454408 · Cited by 186
“Functional improvement of dystrophic muscles in mice has been attained by myostatin blockade (Bogdanovich et al. 2002).”
BackgroundMechanisms Limiting Body Growth in Mammals
Lui, J. C., & Baron, J. (2011) · Endocrine Reviews · doi:10.1210/er.2011-0001 · Cited by 169
Muscle–bone interactions: basic and clinical aspects
Cianferotti, L., & Brandi, M. L. (2014) · Endocrine · doi:10.1007/s12020-013-0026-8 · Cited by 167
Contractile properties of EDL and soleus muscles of myostatin-deficient mice
Mendias, C. L., Marcin, J. E., Calerdon, D. R., & Faulkner, J. A. (2006) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00126.2006 · Cited by 162
“The increased satellite cell activity produced by the deficiency of myostatin does not explain how myostatin deficiency decreases the fibrosis normally present in dystrophic muscle (4, 5, 63) and following snake venom-induced muscle injury (40, 62).”
BackgroundInfluentialRedundancy of myostatin and growth/differentiation factor 11 function
McPherron, A. C., Huynh, T. V., & Lee, S.-J. (2009) · BMC Developmental Biology · doi:10.1186/1471-213x-9-24 · Cited by 165
“Injection of myostatin antagonists also causes a significant increase in muscle mass in normal and dystrophic adult mice demonstrating that myostatin function is not restricted to developmental stages [12-17].”
BackgroundTSUCHIDA, K., NAKATANI, M., UEZUMI, A., MURAKAMI, T., & CUI, X. (2008) · Endocrine Journal · doi:10.1507/endocrj.kr-110 · Cited by 163
The myostatin gene: physiology and pharmacological relevance
JOULIAEKAZA, D., & CABELLO, G. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.11.011 · Cited by 161
Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders
Smith, R. C., & Lin, B. K. (2013) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000013 · Cited by 170
Qiao, C., Li, J., Jiang, J., Zhu, X., Wang, B., Li, J., & Xiao, X. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.159 · Cited by 175
Pharmacological advances for treatment in Duchenne muscular dystrophy
Guiraud, S., & Davies, K. E. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.04.002 · Cited by 159
Identification of a Novel Pool of Extracellular Pro-myostatin in Skeletal Muscle
Anderson, S. B., Goldberg, A. L., & Whitman, M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706678200 · Cited by 160
New insights into the pathogenesis and treatment of sarcopenia in chronic heart failure
Yin, J., Lü, X., Qian, Z., Xu, W., & Zhou, X. (2019) · Theranostics · doi:10.7150/thno.33000 · Cited by 175
“It has been suggested that myostatin is a primary target of pharmacological interventions in muscle atrophy and wasting [117,118].”
BackgroundMuscle Diseases: The Muscular Dystrophies
McNally, E. M., & Pytel, P. (2007) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.2.010506.091936 · Cited by 158
“In addition, myostatin inhibition in the background of the mdx mouse that lacks dystrophin also produced larger and stronger muscles (109).”
BackgroundBrunelli, S., Sciorati, C., D’Antona, G., Innocenzi, A., Covarello, D., Gálvez, B. G., Perrotta, C., Monopoli, A., Sanvito, F., Bottinelli, R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608277104 · Cited by 162
Myostatin Regulates Cardiomyocyte Growth Through Modulation of Akt Signaling
Morissette, M. R., Cook, S. A., Foo, S., McKoy, G., Ashida, N., Novikov, M., Scherrer‐Crosbie, M., Li, L., Matsui, T., Brooks, G., et al. (2006) · Circulation Research · doi:10.1161/01.res.0000231290.45676.d4 · Cited by 162
Myostatin: A novel insight into its role in metabolism, signal pathways, and expression regulation
Huang, Z., Chen, X., & Chen, D. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.05.003 · Cited by 176
Molecular and Cellular Determinants of Skeletal Muscle Atrophy and Hypertrophy
Sartorelli, V., & Fulco, M. (2004) · Science s STKE · doi:10.1126/stke.2442004re11 · Cited by 155
“Accordingly, antibody-mediated myostatin blockade effectively ameliorates anatomical and physiological muscle parameters in the mdx mouse (42).”
Background
Metadata
- Authors
- Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S.
- Affiliations
- University of Pennsylvania (US)
- Pfizer (United States) (US)
- Corresponding author
- Khurana, Tejvir S.
- Venue
- Nature
- Published
- 2002-11
- Volume
- 420
- Issue
- 6914
- Pages
- 418-421
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2083700023
- Semantic Scholar
- 590fb54cd1f2d89d44f4e1ad999be802dc756277
- Cited by
- 831
- References
- 31
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 19 · 2023: 15 · 2022: 21 · 2021: 20 · 2020: 23 · 2019: 32 · 2018: 23 · 2017: 34 · 2016: 28 · 2015: 43 · 2014: 34 · 2013: 38 · 2012: 48
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Keywords
- myostatin, Duchenne muscular dystrophy, mdx mice, muscle atrophy, blocking antibodies, muscle mass, muscle strength, muscle degeneration, creatine kinase, TGF-beta superfamily, skeletal muscle growth
- MeSH terms
- Animals, Antibodies, Body Weight, Creatine Kinase, Male, Muscular Dystrophy, Animal, Organ Size, Transforming Growth Factor beta, Mice, Inbred mdx, Muscle, Skeletal, Muscle Fibers, Skeletal, Muscular Dystrophy, Duchenne, Mice, Myostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.